Search results
Showing 121 to 135 of 173 results for asthma
This guideline sets out an antimicrobial prescribing strategy for acute sore throat. It aims to limit antibiotic use and reduce antimicrobial resistance. Acute sore throat is often caused by a virus, lasts for about a week, and most people get better without antibiotics. Withholding antibiotics rarely leads to complications.
Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza (TA158)
Evidence-based recommendations on oseltamivir (Tamiflu), amantadine (Lysovir or Symmetrel) or zanamivir (Relenza) to prevent influenza (flu).
Amantadine, oseltamivir and zanamivir for the treatment of influenza (TA168)
Evidence-based recommendations on amantadine (Lysovir), oseltamivir (Tamiflu) and zanamivir (Relenza) for treating influenza in children and adults.
Evidence-based recommendations on multiplex allergen testing, using ImmunoCAP ISAC 112 in people with allergy that is difficult to diagnose.
This guidance has been updated and replaced by NICE indicator 273.
This guidance has been updated and replaced by NICE indicator 272.
This evidence summary has been updated and replaced by NICE guideline NG80.
We have moved interventional procedures guidance 635 to become HealthTech guidance 494. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
This guidance has been updated and replaced by NICE interventional procedures guidance 635.
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (TA708)
Evidence-based recommendations on budesonide as an orodispersible tablet for inducing remission of eosinophilic oesophagitis in adults.
Asthma: fluticasone/formoterol (Flutiform) combination inhaler (ESNM3)
This evidence summary has been updated and replaced by NICE guideline NG80.
This guidance has been replaced by NICE technology appraisal guidance 278.
NICE has developed a medtech innovation briefing (MIB) on Lifelight First for monitoring vital signs .
Mepolizumab for treating severe refractory eosinophilic asthma (TA431)
This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 671.
Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.